In this study, the safety and efficacy of cobolimab plus dostarlimab, a PD-1 inhibitor, in patients with locally advanced/metastatic melanoma who were either immunotherapy-naïve or had progressed on prior anti–PD-(L)1 therapy, are reported. This evidence concerns the gene CD274 and metastatic melanoma.